PNNL has named Biomedical Scientist Tom Metz, an expert on metabolomics and multi-omics within the Biological Sciences Division, a 2023 Laboratory Fellow.

Small teams in the Biological Sciences Division at PNNL and at EMSL—the Environmental and Molecular Sciences Laboratory, an Office of Science user facility at PNNL—are pros at preparation.

Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.

Joshua Adkins and Jamie Lo will lead PMedIC, Pacific Northwest National Laboratory and Oregon Health & Science University’s joint research institute.

PNNL scientists are creating new ways to learn more about the vast sea of chemicals that haven't been identified—yet.

Metabolomics analysis revealed differences in metabolome profiles for two distinct modes of fungal wood decay.

Methods review suggests ways to use artificial intelligence and machine learning to handle missing data when integrating two or more omics approaches.

As the world races to discover solutions for reaching net zero carbon emissions, a PNNL analysis quantifies the economic value of the existing nuclear power fleet and its carbon-free energy contributions.

PNNL’s Isabella van Rooyen leads the JOM special section on Additive Manufacturing for High Temperature Energy Systems.

PNNL chemist Christopher Anderton recently named president-elect of the Imaging Mass Spectrometry Society (IMSS). In this new position, he will help lead the merge of IMSS with a European-based society, currently underway.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.

Exploring why some brains are more resilient to the impact of Alzheimer’s disease could lead to improved diagnoses, treatment and prevention.

Advanced proteomic analysis tools dig deep into human blood plasma to understand the molecular nature of advanced alcoholic disease.

A detailed snapshot of proteins by PNNL scientists marks a big step toward a diagnostic blood test for a deadly form of liver disease.

PNNL will partner with Commonwealth Fusion Systems to develop innovative steel materials for fusion applications under the INFUSE program

Tungsten heavy alloys show promise for nuclear fusion energy development, according to new research conducted at PNNL.

Findings show method to better prepare human lung tissue for study; it represents the latest mass spectrometry-based omics advances.

New research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. The findings outline a biological classification system that predicts disease severity.

Advancing the science of radiation, especially among students at minority-serving institutions, is the goal of one of the Department of Energy’s newest consortia.

David Senor has been selected for the Department of Energy’s Fusion Energy Sciences Advisory Committee.